Form 4: Edgewise Therapeutics CSO Alan J. Russell Acquires Stock Options and Restricted Stock Units
SEC Form 4
Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, acquired stock options and restricted stock units on August 12, 2024, according to a Form 4 filing.
Summary
- On August 12, 2024, Alan J. Russell, the Chief Scientific Officer of Edgewise Therapeutics, Inc., acquired stock options and restricted stock units.
- Russell acquired options to purchase 138,750 shares of common stock at an exercise price of $17.05, vesting monthly over four years.
- He also acquired 23,125 restricted stock units (RSUs), each representing a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock, vesting annually over four years.
- Following these transactions, Russell directly owns 138,750 derivative securities and 23,125 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock options and RSU grants, which are typical components of executive compensation. It doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options and RSUs by the Chief Scientific Officer aligns his interests with those of the shareholders.
- The vesting schedules of both the options and RSUs incentivize long-term commitment and performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests and assess management's confidence in the company's future prospects. This is a routine disclosure and doesn't necessarily indicate a significant shift in the company's outlook.
Comparison to Industry Standards
- Stock option and RSU grants are common compensation practices in the biotechnology industry to incentivize executives.
- Vesting schedules, such as monthly or annual installments over several years, are also standard to ensure long-term commitment.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- The acquisition of stock options and RSUs by a key executive can potentially align the executive's interests with those of the shareholders, encouraging decisions that benefit the company's long-term value.
- Employees may view this as a positive sign, indicating the company's commitment to incentivizing its leadership.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the transaction: Alan J. Russell acquired stock options and restricted stock units. |
| 08/12/2024 | Vesting start date for stock options: 1/48th of the shares vest each month beginning on this date. |
| 08/12/2024 | Vesting start date for RSUs: RSUs vest in four equal annual installments beginning on this date. |
| 08/12/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.